The Quantellect read.As of Nov 19, 2026, 4 active firms cover iBio, Inc. Common Stock: 4 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $5.00 to $7.00, a moderate spread. The average target of $6.00 sits 635% above the current $0.82. The rating mix has stayed broadly stable, with Buy-side ratings easing from 5 to 4 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.08 next quarter toward $-0.52 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 active firms
Buy
Strong Buy00%
Buy4100%
Neutral00%
Sell00%
Strong Sell00%
Based on 4 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$6.00
+634.6% upside
Average target across 4 active firms as of Nov 19, 2026 vs $0.82 current
Highest Target$7.00
Average Target$6.00
Lowest Target$5.00
Detailed analyst forecasts for IBIO
Showing 1–4 of 4 named analysts shown · 4 active firms in the rating projection
As of Nov 19, 2026, 4 of 4 active firms rate IBIO a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
IBIO EPS & revenue forecast
EPS · NEXT QUARTER
$-0.08
Range $-0.16 – $-0.06 · 9 analysts
Next period, 9 analysts expect iBio, Inc. Common Stock to earn $-0.08 a share (range $-0.16 – $-0.06), versus — a year earlier. Full-year consensus is $-0.33, growing to $-0.52 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 9 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $1.1M, rising to $220.0K next year.
Top analysts covering iBio, Inc. Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IBIO.
#1
Keay Nakae
Chardan Capital · Rank #130
Buy
$5.00+512.1% to target
Overall win rate
41%
+ Follow
#2
Jay Olson
Oppenheimer · Rank #484
Buy
$5.00+512.1% to target
Overall win rate
31%
+ Follow
#3
Roanna Ruiz
SVB Leerink · Rank #513
Buy
$6.00+634.6% to target
Overall win rate
30%
+ Follow
#4
Martin Auster
Raymond James
Buy
$5.00+512.1% to target
Coverage
—
+ Follow
#5
CN
Catherine Novack
JonesTrading
Buy
$7.00+757.0% to target
Coverage
—
+ Follow
IBIO stock forecast FAQ
What is IBIO's average 12-month price target?+
The 4 active firms with a live target average $6.00 for iBio, Inc. Common Stock over the next 12 months, ranging from a $7.00 high to a $5.00 low, as of Nov 19, 2026.
Is IBIO stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 4 active firms as of Nov 19, 2026, 4 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for IBIO?+
The Street-high target is $7.00 (HC Wainwright & Co.), and the Street-low is $5.00 (Chardan Capital). The average of all 4 active-firm targets is $6.00.
How many active Wall Street firms cover IBIO?+
4 active firms have a recognized rating on iBio, Inc. Common Stock as of Nov 19, 2026, and 4 active firms carry a live 12-month price target.
Who is the most accurate analyst covering IBIO?+
Among analysts who currently cover IBIO, Keay Nakae of Chardan Capital has the strongest overall Quantellect track record (Rank #130). Their current call is Buy with a $5.00 target.
What is iBio, Inc. Common Stock's projected EPS for next quarter?+
The consensus estimate is $-0.08 per share (range $-0.16 – $-0.06) across 9 analysts. Full-year EPS is projected at $-0.33, rising to $-0.52 the following year.
How much revenue is iBio, Inc. Common Stock expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $1.1M, growing to $220.0K next year.
Have analysts been upgrading or downgrading IBIO lately?+
As of Nov 19, 2026, 4 of 4 active firms rate IBIO a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IBIO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.